Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Cardiovascular Medicine
Erschienen in: Current Treatment Options in Cardiovascular Medicine 4/2017

01.04.2017 | Vascular Disease (I Weinberg, Section Editor)

Acute Aortic Syndromes: Update in Current Medical Management

verfasst von: Jacqueline H. Morris, DO, Doran Mix, MD, Scott J. Cameron, MD, PhD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Opinion statement

Advances in medical therapy and non-surgical percutaneous options to manage the specter of acute aortic syndromes have improved both patient morbidity and mortality. There are key features in the patient history and initial exam which physicians should be attuned to in order to diagnose acute aortic syndromes such as aortic dissection, penetrating aortic ulcer, and intramural hematoma. Once recognized, early initiation of the appropriate pharmacologic therapy is important, and further appreciating the limitations of such therapy before considering a surgical approach is critical to improve patient outcomes. For the undifferentiated patient with acute aortic dissection presenting to facilities who do not routinely manage this condition, adding pharmacologic agents in the correct sequence assures the best chance for a satisfactory outcome.
Literatur
1.
•• Mussa FF et al. Acute aortic dissection and intramural hematoma: a systematic review. JAMA. 2016;316(7):754–63. This manuscript offers a current, concise summary of what constitutes an acute aortic syndrome, including summaries of major clinical trials.
2.
3.
Howard DP et al. Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control: 10-year results from the Oxford Vascular Study. Circulation. 2013;127(20):2031–7.CrossRefPubMed
4.
Nienaber CA, Powell JT. Management of acute aortic syndromes. Eur Heart J. 2012;33(1):26–35b.CrossRefPubMed
5.
Kawabori M, Kaneko T. Acute aortic syndrome: a systems approach to a time-critical disease. Best Pract Res Clin Anaesthesiol. 2016;30(3):271–81.CrossRefPubMed
6.
Harris KM et al. Acute aortic intramural hematoma: an analysis from the International Registry of Acute Aortic Dissection. Circulation. 2012;126(11 Suppl 1):S91–6.CrossRefPubMed
7.
Debakey ME et al. Surgical management of dissecting aneurysms of the aorta. J Thorac Cardiovasc Surg. 1965;49:130–49.PubMed
8.
Daily PO et al. Management of acute aortic dissections. Ann Thorac Surg. 1970;10(3):237–47.CrossRefPubMed
9.
10.
Beaulieu RJ, et al. Surgical management of peripheral vascular manifestations of Loeys-Dietz syndrome. Ann Vasc Surg, 2016; 1–7
11.
Kalkat MS et al. Presentation and outcome of Marfan’s syndrome patients with dissection and thoraco-abdominal aortic aneurysm. Eur J Cardiothorac Surg. 2007;32(2):250–4.CrossRefPubMed
12.
Regalado E et al. Autosomal dominant inheritance of a predisposition to thoracic aortic aneurysms and dissections and intracranial saccular aneurysms. Am J Med Genet A. 2011;155A(9):2125–30.CrossRefPubMed
13.
14.
von Kodolitsch Y, Csösz S, Koschyk DH, Schalwat I, Loose R, Karck M, et al. Intramural hematoma of the aorta: predictors of progression to dissection and rupture. Circulation. 2003;107(8):1158–63.CrossRef
15.
Stanson AW et al. Penetrating atherosclerotic ulcers of the thoracic aorta: natural history and clinicopathologic correlations. Ann Vasc Surg. 1986;1(1):15–23.CrossRefPubMed
16.
Cooke JP, Kazmier FJ, Orszulak TA. The penetrating aortic ulcer: pathologic manifestations, diagnosis, and management. Mayo Clin Proc. 1988;63(7):718–25.CrossRefPubMed
17.
Coady MA, Rizzo JA, Elefteriades JA. Pathologic variants of thoracic aortic dissections. Penetrating atherosclerotic ulcers and intramural hematomas. Cardiol Clin. 1999;17(4):637–57.CrossRefPubMed
18.
Andersen ND et al. Outcomes of acute type a dissection repair before and after implementation of a multidisciplinary thoracic aortic surgery program. J Am Coll Cardiol. 2014;63(17):1796–803.CrossRefPubMedPubMedCentral
19.
Harris KM et al. Multidisciplinary standardized care for acute aortic dissection: design and initial outcomes of a regional care model. Circ Cardiovasc Qual Outcomes. 2010;3(4):424–30.CrossRefPubMed
20.
Hagan PG et al. The International Registry of Acute Aortic Dissection (IRAD). JAMA. 2000;283(7):897.CrossRefPubMed
21.
Chan KK, Lai P, Wright JM. First-line beta-blockers versus other antihypertensive medications for chronic type B aortic dissections. Cochrane Database Syst Rev. 2014;2:1–9.
22.
LeMaire SA, Russell L. Epidemiology of thoracic aortic dissection. Nat Rev Cardiol. 2011;8(2):103–13.CrossRefPubMed
23.
Silaschi M, Byrne J, Wendler O. Aortic dissection: medical, interventional and surgical management. Heart. 2016. Epub ahead of print
24.
Robbins RC et al. Management of patients with intramural hematoma of the thoracic aorta. Circulation. 1993;88(5 Pt 2):II1–II10.PubMed
25.
Evangelista A et al. Acute intramural hematoma of the aorta: a mystery in evolution. Circulation. 2005;111(8):1063–70.CrossRefPubMed
26.
Girardi LN, Al’Aref SJ, Devereux R, Lau C, Ghosh BD. Swaminathan RV. A contemporary review of acute aortic dissection. Emergency Medicine: Open Access. 2015;05(05):1–10.
27.
Suzuki T et al. Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International Registry of Aortic Dissection (IRAD). Circulation. 2003;1 Suppl 1:II312-7.
28.
•• Erbel R et al. ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(41):2873–926. This manuscript is the most up-to-date, concise consensus statement focusing on detection, diagnosis, and monitoring of patients with acute aortic syndromes. It is particularly useful is guiding surveillance for patients with congenital aortopathies.
29.
Hiratzka LF et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J Am Coll Cardiol. 2010;55(14):e27–e129.CrossRefPubMed
30.
Suzuki T et al. Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol. 2012;109(1):122–7.CrossRefPubMed
31.
Sakakura K et al. Determinants of long-term mortality in patients with type B acute aortic dissection. Am J Hypertens. 2009;22(4):371–7.CrossRefPubMed
32.
Takeshita S et al. Angiotensin-converting enzyme inhibitors reduce long-term aortic events in patients with acute type B aortic dissection. Circ J. 2008;72(11):1758–61.CrossRefPubMed
33.
Owens 3rd AP et al. Platelet inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35(9):2032–41.CrossRefPubMedPubMedCentral
34.
Schouten O et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32(1):21–6.CrossRefPubMed
35.
Wemmelund H et al. Statin use and rupture of abdominal aortic aneurysm. Br J Surg. 2014;101(8):966–75.CrossRefPubMed
36.
Saborio DV et al. Management of intramural hematoma of the ascending aorta and aortic arch: the risks of limited surgery. Tex Heart Inst J. 2003;30(4):325–7.PubMedPubMedCentral
37.
Li DL et al. Acute type B aortic intramural hematoma: treatment strategy and the role of endovascular repair. J Endovasc Ther. 2010;17(5):617–21.CrossRefPubMed
38.
Zhang G, Feng Q, Zheng D. Early aggressive medical treatment associatd with selective prophylactic aortic stent-grafting for aortic intramural hematoma. Thorac Cardiovasc Surg. 2011;59(6):342–8.CrossRefPubMed
39.
Canadas MV et al. Intramural aortic hematoma and anticoagulation. Rev Esp Cardiol. 2007;60(2):201–4.CrossRefPubMed
40.
El Hassani I et al. Penetrating atherosclerosis aortic ulcer: a re-appraisal. Acta Chir Belg. 2016;3:1–7.
41.
Patatas K, Shrivastava V, Ettles DF. Penetrating atherosclerotic ulcer of the aorta: a continuing debate. Clin Radiol. 2013;68(8):753–9.CrossRefPubMed
42.
Ganaha F et al. Prognosis of aortic intramural hematoma with and without penetrating atherosclerotic ulcer:a clinical and radiological analysis. Circulation. 2002;106:342–8.CrossRefPubMed
43.
Fattori R et al. Complicated acute type B dissection: is surgery still the best option?: a report from the International Registry of Acute Aortic Dissection. JACC Cardiovasc Interv. 2008;1(4):395–402.CrossRefPubMed
44.
Booher AM et al. Ascending thoracic aorta dimension and outcomes in acute type B dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol. 2011;107(2):315–20.CrossRefPubMed
45.
Nienaber CA et al. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv. 2013;6(4):407–16.CrossRefPubMed
46.
Muehle A et al. Experiences with ascending aortic endografts using FDA IDE approved devices. What has been done, what lesions can be treated and what challenges remain. J Cardiovasc Surg (Torino). 2015;56(1):11–8.
47.
• Cambria RP, Conrad MF. Thoracic endovascular aneurysm repair for uncomplicated type B dissection. J Vasc Surg. 2016;64(6):1558–9. At the time of writing this review, this article summarizes endovascular options for managing Type B aortic dissections with available evidence.
48.
• Durham CA et al. The natural history of medically managed acute type B aortic dissection. J Vasc Surg. 2015;61(5):1192–8. This article is a large registry spanning more than a decade which describes the outcomes in patients managed medically for Type B Aortic Dissections. This article is useful in appreciating the surgeon's viewpoint of medical management for Type B Aortic Dissection.
49.
Scali ST et al. Efficacy of thoracic endovascular stent repair for chronic type B aortic dissection with aneurysmal degeneration. J Vasc Surg. 2013;58(1):10-7 e1.PubMedCentral
Metadaten
Titel
Acute Aortic Syndromes: Update in Current Medical Management
verfasst von
Jacqueline H. Morris, DO
Doran Mix, MD
Scott J. Cameron, MD, PhD
Publikationsdatum
01.04.2017
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 4/2017
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-017-0523-9

Weitere Artikel der Ausgabe 4/2017

Current Treatment Options in Cardiovascular Medicine 4/2017 Zur Ausgabe

Heart Failure (W Tang, Section Editor)

Targeting the Microbiome in Heart Failure

Cardio-oncology (M Fradley, Section Editor)

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia

Vascular Disease (I Weinberg, Section Editor)

Novel and Advanced Techniques for Complex IVC Filter Retrieval

Heart Failure (W Tang, Section Editor)

Targeting Frailty in Heart Failure

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Management of Percutaneous Coronary Intervention Complications

Regenerative Medicine and Stem-cell Therapy (S Wu and P Hsieh, Section Editors)

Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise